NEW YORK (GenomeWeb News) – Asuragen has raised $7.5 million toward a targeted $15 million round.

The Austin, Texas-based molecular diagnostics firm disclosed the funding in a document filed this week with the US Securities and Exchange Commission. Company President and CEO Rollie Carlson said that existing investors participated in the raise, which will go toward the commercialization of Asuragen's oncology and genetic disease tests.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.